Quidel Corporation

Quidel Corporation Earnings Recaps

QDEL Health Care 2 recaps
Q1 2026 May 8, 2026

The stock dropped 7.6% following earnings as investors were disappointed by lower-than-expected guidance driven by a sharp deceleration in respiratory revenue amid a significantly softer flu season and margin pressures from evolving pricing regulations in China.

Key takeaways
  • Total reported revenue was $620 million with labs revenue down 8%, weighed by termination of a joint business agreement and ongoing macroeconomic headwinds in China.
  • Respiratory revenue declined sharply to $68 million due to approximately 30% fewer ILI visits versus Q1 2025, reflecting a milder and shorter respiratory season.
  • Chinese sales slowed in March with ongoing cautious distributor inventory management ahead of pending IVD pricing guideline changes anticipated mid-2027, impacting near-term revenue and margins.
  • Immunohematology showed a modest 3% growth driven by North America, China, and JPAC despite broader pressures.
  • The company is preparing mitigation actions for the pricing impact in China but anticipates these headwinds will weigh on full-year guidance and margins.
Full recap
Q3 2025 Nov 6, 2025

QuidelOrtho reported solid Q3 2025 results, showcasing organic sales growth of 5% and an adjusted EBITDA margin of 25%, reflecting strong performance across its diversified diagnostics portfolio.

Key takeaways
  • Organic sales growth of 5%, excluding COVID and the U.S. donor screening business, driven by strong demand in labs, immunohematology, and point-of-care sectors.
  • Adjusted EBITDA increased to $177 million, with a margin improvement of 180 basis points year-over-year.
  • Latin America led growth outside the U.S. with a 21% increase, while overall international revenue demonstrated strong momentum.
  • Successful FDA clearance of the new VITROS high-sensitivity troponin assay, enhancing the cardiac testing portfolio and potential for reduced hospital admissions.
  • Ongoing cost optimization initiatives have resulted in over $140 million in savings, setting the stage for sustainable mid- to high-20s EBITDA margins.
Full recap